Table 2. Baseline characteristics of 291 patients with one mutation by the type of therapy.
| Covariate | Matched (%) (n = 175) |
Nonmatched (%) (n = 116) |
P | |
|---|---|---|---|---|
| Age, y | <60 | 96 (55) | 61 (53) | 0.80 |
| ≥60 | 79 (45) | 55 (47) | ||
| Sex | Male | 86 (49) | 47 (41) | 0.19 |
| Female | 89 (51) | 69 (59) | ||
| Number of prior therapies | ≤3 | 55 (31) | 33 (28) | 0.68 |
| >3 | 120 (69) | 83 (72) | ||
| Performance status | 0 | 52 (30) | 38 (33) | 0.77 |
| 1 | 113 (65) | 73 (63) | ||
| 2+ | 10 (6) | 5 (4) | ||
| Platelet count, × 109/L | <140 | 25 (14) | 20 (17) | 0.78 |
| ≥140–<440 | 143 (82) | 92 (79) | ||
| ≥440 | 7 (4) | 4 (3) | ||
| Number of metastatic sites | ≤2 | 101 (58) | 71 (61) | 0.64 |
| >2 | 74 (42) | 45 (39) | ||
| Liver metastases | Yes | 97 (55) | 74 (64) | 0.20 |
| No | 78 (45) | 42 (36) | ||
| Lactate dehydrogenase ≥ 618 IU/L | Yes | 50 (29) | 47 (41) | 0.05 |
| No | 125 (71) | 69 (59) | ||
| Albumin < 3.5 g/dL | Yes | 17 (10) | 8 (7) | 0.53 |
| No | 158 (90) | 108 (93) | ||
| Royal Marsden Hospital score | 0 or 1 | 133 (76) | 92 (79) | 0.61 |
| 2 or 3 | 42 (24) | 24 (21) |